Home > Analytics > JUBILANT PHARMOVA

JUBILANT PHARMOVA
Intrinsic Value | Fundamental Analysis

BOM : 530019     NSE : JUBLPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 06,2025
Price(EOD): ₹ 1,139.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 18,153.83 Cr
Value of ₹ 1 Lac invested in JUBILANT PHARMOVA
on Jun 08,2020 (price: ₹ 569.85)

₹ 1 L

₹ 2.00 L

1W : -2.6% 1M : 29.7% 1Y : 70.1%
COMMUNITY POLL
for JUBILANT PHARMOVA
Please provide your vote to see the results
JUBILANT PHARMOVA is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
JUBILANT PHARMOVA -2.6% 29.7% 70.1%
SUN PHARMACEUTICAL INDUSTRIES 0.3% -4.9% 15.8%
DIVIS LABORATORIES 0.2% 10% 53.5%
CIPLA 2.3% 1.1% 2.6%
TORRENT PHARMACEUTICALS 0.8% -0.9% 17.4%
DR REDDYS LABORATORIES 5.7% 15% 11.5%
MANKIND PHARMA -2.5% -3.3% 11.1%
ZYDUS LIFESCIENCES 3.3% 10.1% -7.4%
LUPIN 2% -0.7% 26%

FUNDAMENTAL ANALYSIS OF JUBILANT PHARMOVA

 
Fundamentals Score
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF JUBILANT PHARMOVA

 
Valuation Score
[As on : Jun 06,2025 ]

Ratio Consolidated
P/E
P/B
P/S
21.69
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 836.80 Cr
[Latest Qtr - Mar2025 - Consolidated Results ]

2.9
P/B Calculated based on Book Value of Rs 6,254.90 Cr
[Latest Year - Mar2025 - Consolidated Results ]

2.51
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 7,234.50 Cr
[Latest Qtr - Mar2025 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 17% undervalued companies ! Discover More →

FAIR VALUE OF JUBILANT PHARMOVA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
244%
86%
90%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF JUBILANT PHARMOVA


Insights 💡 JUBLPHARMA is one of the top 73% companies with bullish price momentum currently! Discover More →

JUBILANT PHARMOVA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF JUBILANT PHARMOVA

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.15
0.13
0.07
0.12
0.63
0.63
0.55
0.6
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF JUBILANT PHARMOVA

Pledged Promoter Shares
0 %
As on : Mar2025

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF JUBILANT PHARMOVA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
5.88%
20.18%
57.57%
49.9%
9.68%
27.27%
460.95%
332.21%
QtrlyTrend
8
Latest Qtr: Mar2025
Quarterly Result Analysis →


JUBILANT PHARMOVA related INDICES

BSE Indices1W1M1Y
BSE ALLCAP 6.4% 8.9% 7.5%
BSE MIDSMALLCAP 4.7% 9% 8.4%
BSE 500 SHARIAH 4.3% 4.3% 1.1%
BSE 400 MIDSMALLCAP INDEX 2.4% 9.1% 10.2%
BSE 250 SMALLCAP INDEX 2.3% 11.7% 9.7%
NSE Indices1W1M1Y
NIFTY500 MOMENTUM 50 3.4% 8.3% NA
NIFTY SMALLCAP 250 2.7% 12.5% 10.6%
NIFTY MIDSMALLCAP 400 2.7% 10.1% 11.7%
NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX 2.2% 8.1% NA
NIFTY 500 EQUAL WEIGHT 2.1% 10.7% NA

You may also like the below Video Courses


FAQ about JUBILANT PHARMOVA


Is JUBILANT PHARMOVA good for long term investment?

As on Jun 06,2025, the Fundamentals of JUBILANT PHARMOVA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of JUBILANT PHARMOVA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is JUBILANT PHARMOVA UnderValued or OverValued?

As on Jun 06,2025, JUBILANT PHARMOVA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of JUBILANT PHARMOVA ?

As on Jun 06,2025, the Intrinsic Value of JUBILANT PHARMOVA is Rs. 598.29 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 331.16
Fair Value [Median EV / Sales Model] : Rs. 611.28
Fair Value [Median Price / Sales Model] : Rs. 598.29
Estimated Median Fair Value of JUBILANT PHARMOVA : Rs. 598.29

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is JUBILANT PHARMOVA trading at a Premium or Discount?

As on Jun 06,2025, JUBILANT PHARMOVA is trading at a Premium of 90% based on the estimates of Median Intrinsic Value!